Recent advances in nanotechnology and material science have re-ignited interest in drug delivery research. Arguably, however, hardly any of the systems developed and strategies proposed are really relevant for shaping the future (clinical) face of the nanomedicine field. Consequently, as outlined in this commentary, instead of making ever more carrier materials, and making nanomedicine both science-fiction and fiction-science, we should try to come up with rational and realistic concepts to make nanomedicines work, in particular in patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745778 | PMC |
| http://dx.doi.org/10.1016/j.ijpharm.2013.02.046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Coated Balloons for the Treatment of Coronary Artery Disease: A Review.
JAMA Cardiol
December 2024
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Importance: Drug-coated balloon (DCB) angioplasty has emerged as an alternative to drug-eluting stent (DES) implantation for percutaneous coronary intervention (PCI) in patients with coronary in-stent restenosis (ISR) as well as de novo coronary artery disease.
Observations: DCBs are balloons coated with antiproliferative agents and excipients, whose aim is to foster favorable vessel healing after appropriate lesion preparation. By providing homogeneous antiproliferative drug delivery in the absence of permanent foreign body implantation, DCBs offer multiple advantages over DES, including preservation of vessel anatomy and function and positive vessel remodeling.
This review delves into the evolving landscape of mediated drug delivery, focusing on the versatility of a variety of drug delivery vehicles such as microspheres, microbots, and nanoparticles (NPs). The review also expounds on the critical components and mechanisms for light-mediated drug delivery, including photosensitizers and light sources such as visible light detectable by the human eye, ultraviolet (UV) light, shorter wavelengths than visible light, and near-infrared (NIR) light, which has longer wavelength than visible light. This longer wavelength has been implemented in drug delivery for its ability to penetrate deeper tissues and highlighted for its role in precise and controlled drug release.
View Article and Find Full Text PDFUnlocking the Potential of Carrier Mediated Nano-biomedicine in Management of Diabetes Mellitus: A review.
Chem Biodivers
December 2024
Dr Dayaram Patel Pharmacy College, Pharmaceutics, Bardoli, 394601, Bardoli, INDIA.
Diabetes is a medical condition, which belongs to the group of chronic diseases that affects how body processes glucose, the primary source of energy for cells. Glucose comes indirectly from the consumed food and is carried by bloodstream to various cells in body. Insulin, a hormone synthesized by pancreas play a vital role in conversion of glucose to energy.
View Article and Find Full Text PDFEnDM-CPP: A Multi-view Explainable Framework Based on Deep Learning and Machine Learning for Identifying Cell-Penetrating Peptides with Transformers and Analyzing Sequence Information.
Interdiscip Sci
December 2024
School of Computer Science and Artificial Intelligence, Aliyun School of Big Data, School of Software, Changzhou University, Changzhou, 213164, China.
Cell-Penetrating Peptides (CPPs) are a crucial carrier for drug delivery. Since the process of synthesizing new CPPs in the laboratory is both time- and resource-consuming, computational methods to predict potential CPPs can be used to find CPPs to enhance the development of CPPs in therapy. In this study, EnDM-CPP is proposed, which combines machine learning algorithms (SVM and CatBoost) with convolutional neural networks (CNN and TextCNN).
View Article and Find Full Text PDFA prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device.
Int J Clin Oncol
December 2024
Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Background: The implementation of cancer precision medicine in Japan is deeply intertwined with insurance reimbursement policies and requires case-by-case reviews by Molecular Tumor Boards (MTBs), which impose considerable operational burdens on healthcare facilities. The extensive preparation and review times required by MTBs hinder their ability to efficiently assess comprehensive genomic profiling (CGP) test results. Despite attempts to optimize MTB operations, significant challenges remain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!